Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Foghorn Therapeutics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
12/04/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 4, 2020 Foghorn Therapeutics Inc. Delaware 001-39634 47-5271393 500 Technology Square, Ste 700 Cambridge, MA 02139 : 245-0399 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rul...",
"- Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration - On track to submit an IND for FHD-286 by year end 2020 and for FHD-609 during the first half of 2021"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy